TCR2 Therapeutics, Inc.

( )
TCRR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.25%162.640.7%$1229.36m
PFEPfizer Inc. 0.99%38.950.9%$1049.85m
MRKMerck & Co., Inc. 0.18%77.610.7%$782.74m
ABBVAbbVie, Inc. 0.76%108.731.9%$744.24m
BMYBristol-Myers Squibb Co. 0.44%65.751.0%$703.61m
LLYEli Lilly & Co. 0.25%189.731.1%$539.14m
AZNAstraZeneca Plc 1.75%51.631.2%$494.28m
GSKGlaxoSmithKline Plc 0.64%37.990.2%$223.56m
NVSNovartis AG 0.40%88.370.2%$162.95m
VTRSViatris, Inc. -1.12%13.250.0%$124.35m
CVACCureVac NV 3.40%113.000.0%$103.24m
RPRXRoyalty Pharma Plc -0.24%41.770.2%$91.76m
RGENRepligen Corp. -0.59%212.046.8%$80.03m
NVONovo Nordisk A/S 0.75%72.710.1%$62.90m
SNYSanofi 1.01%51.820.2%$59.75m

Company Profile

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.